Skip to main content
. 2020 Jun 3;20:277. doi: 10.1186/s12888-020-02687-w

Table 2.

Comparative analysis of patients with normal and prolonged QTc interval

Variables QTc interval p-value
Normal (N = 382) a
n (%)
Prolonged (N = 23) b
n (%)
Gender
 Male 229 (92.3) 19 (7.7) 0.03
 Female 153 (97.5) 4 (2.5)
Age (years)
  ≤ 20 75 (19.6) 6 (26.1) 0.45
 21–30 105 (27.5) 4 (17.4)
 31–40 94 (24.6) 4 (17.4)
  > 40 108 (28.3) 9 (39.1)
All prescribed drugs
 1 47 (12.3) 1 (4.3) 0.48
 2–3 240 (62.8) 15 (65.2)
  > 3 95 (24.9) 7 (30.4)
QT prolonging drugs
 1 216 (56.5) 10 (43.5) 0.22
  ≥ 2 166 (43.5) 13 (56.5)
QT drug-drug interactions 109 (28.5) 9 (39.9) 0.27
Diagnosis
 Psychosis 29 (7.6) 2 (8.7) 0.84
 Manic depressive psychosis 33 (8.6) 10 (13) 0.47
 Obsessive compulsive disorder 16 (4.2) 2 (8.7) 0.30
 Schizophrenia 16 (4.2) 1 (4.3) 0.97
 Major depression 200 (52.4) 11 (47.8) 0.67
 Hypomania 13 (3.4) 0 (0) 0.36
 Panic disorder 34 (8.9) 0 (0) 0.13
 Bipolar affective disorder 11 (2.9) 0 (0) 0.40
 Substance abuse 17 (4.9) 0 (0) 0.30
Co-morbid illnesses
 Hypertension 40 (10.5) 3 (13) 0.67
 Diabetes mellitus 17 (4.5) 0 (0) 0.80
 Epilepsy 13 (3.4) 0 (0) 0.27
QT prolonging drug classes (ATC Code)
 Antipsychotic (N05A) 140 (36.6) 11 (47.8) 0.28
 Proton pump inhibitors (A02BC) 48 (12.6) 1 (4.3) 0.24
 Antidepressant (N06A) 253 (66.2) 14 (60.9) 0.59
 Other drugs 19 (5) 2 (8.7) 0.43

a Percentage calculated in total of 382 patients with normal QTc interval except gender; b Percentage calculated in total of 23 patients with prolonged QTc interval except gender